# Consolidated Results Third Quarter Ended December 31, 2013

1. Overview

- 2. Financial Position
- 3. Segment Information

January 31, 2014 Ajinomoto Co., Inc.

Copyright © 2014 Ajinomoto Co., Inc. All rights reserved.

# **ДІNOMOTO**. 1. (1) Overview of Results

									·· -	
	AprDec. 2013	AprDec. 2012	YoY CI	nange	FY2013 (Nov. Revised Forecast)	Progress	OctDec. 2013	OctDec. 2012	YoY Cł	nange
	(A)		Amount	%	(B)	(A)/(B)			Amount	%
Net sales	742.3	746.9	-4.5	-1%	1,032.0	72%	255.2	240.9	14.3	6%
Domestic Food Products	255.0	314.1	-59.1	-19%	340.5	75%	93.8	92.9	0.9	1%
Overseas Food Products	219.4	175.3	44.1	25%	317.2	69%	74.9	60.5	14.4	24%
Bioscience Products & Fine Chemicals	166.9	146.4	20.5	14%	238.3	70%	55.1	49.4	5.7	11%
Pharmaceuticals	38.8	55.9	-17.1	-31%	51.8	75%	10.9	20.0	-9.1	-46%
Other Business	62.3	55.2	7.0	13%	84.2	74%	20.6	18.1	2.4	13%
Operating income	50.8	60.9	-10.1	-17%	68.0	75%	21.3	24.0	-2.8	-11%
Domestic Food Products	22.8	29.2	-6.4	-22%	27.6	83%	11.8	11.9	-0.1	-1%
Overseas Food Products	19.7	15.4	4.3	28%	26.3	75%	6.9	5.2	1.7	32%
Bioscience Products & Fine Chemicals	5.0	11.3	-6.3	-56%	9.4	53%	1.1	4.1	-3.0	-73%
Pharmaceuticals	2.8	4.6	-1.8	-38%	4.3	66%	1.3	2.8	-1.5	-54%
Other Business	0.4	0.4	0.1	17%	0.4	109%	0.2	0.1	0.1	161%
Ordinary income	56.8	65.8	-9.0	-14%	74.0	77%	23.9	26.5	-2.6	-10%
Net income	37.0	54.4	-17.4	-32%	48.0	77%	14.9	13.3	1.5	11%
Exchange rate JPY/USD	99.36	79.95			98.0					
JPY/EUR	132.17	102.04			131.0					

Notes:

1. Oct.-Dec. results are the difference between Apr.-Dec. results and Apr.-Sept. results (for this and all following slides).

2. Changes due to the introduction of net figure (the method of netting off sales and cost of goods sold and recording the net figure in the accounts) for business tie-ups from FY2013 are as follows:

Scope: Kellogg's products included in the "Seasonings & processed foods" category of Domestic Food Products; the "Edible oils" and "Coffee products" categories of Business Tie-Ups

• The former "Business Tie-Ups" segment has been discontinued. "Edible oils" and "Coffee products" have been reclassified as "Edible oils & coffee products" (net figure) in the "Other Business" segment.

• Results for FY2012 have been restated to reflect the above changes (for this and all following slides).

Copyright © 2014 Ajinomoto Co., Inc. All rights reserved.



# 

# 1. (2) Comments on Results for the First Nine Months of FY2013

Net sales for Oct.-Dec. (hereafter, "Q3") increased mainly due to continuing positive effect of currency translation.

Q3 operating income decreased because decrease in income of feed-use amino acids and Pharmaceuticals was not offset by other businesses.

Net sales / Operating income						(¥ Billion)
	AprDec. 2013	Progress	YoY Change		OctDec. 2013	YoY Change
	742.3	72%	-1%	Net sales	255.2	6%
	473.9	-	6%	Cost of sales	160.3	10%
	217.6	-	-9%	SG&A	73.6	4%
	50.8	75%	-17%	Operating income	21.3	-11%

1. Impact of	Exchang	ge rate for currency translation	
exchange rate	Q3:	Sales ¥20.4 billion; operating income ¥1.7 billion	on
(YoY)	AprDee	c.: Sales ¥65.7 billion; operating income ¥6.2 billio	on
	Exchang	ge rate for trade of main overseas subsidiaries	
	Q3:	Sales approx. ¥1.0 billion; operating income ap	oprox. ¥0.0 billion
	AprDee	c.: Sales approx. ¥3.5 billion; operating income ap	oprox¥0.5 billion
2. Impact of raw material &	Q3:	Fermentation raw materials and fuel prices app Domestic food products raw materials approx.	
fuel prices (YoY)	AprDee	c.: Fermentation raw materials and fuel prices app Domestic food products raw materials approx.	
3. Cost reductions	Q3:	Domestic food products approx. ¥1.3 billion; P	
(YoY)	AprDee	c.: Domestic food products approx. ¥2.8 billion; P	harmaceuticals approx. ¥1.0 billion
			(: Cost increase)




# ▲JINOMOTO. 1. (3) Comments on Results for the First Nine Months of FY2013


Ordina	ry inco	me			(¥ Billion)	
AprDec. 2013	Progress	YoY Change		OctDec. 2013	YoY Change	< Q3 > ()= YoY change None
6.0	-	24%	Non-operating income (net)	2.6	6%	< AprDec. Cumulative > ( )=YoY change
56.8	77%	-14%	Ordinary income	23.9	-10%	None
Net inc AprDec. 2013	Progress	YoY Change		OctDec. 2013	(¥ Billion) YoY Change	< Q3 > ()= YoY change * Gain on sales of shares in affiliated companies ¥0.0 billion (¥17.6 billion decrease) * Impairment losses ¥0.0 billion (¥7.2 billion decrease)
3.8 2.8 15.0 5.7 37.0	-	-92% -76% -65% 12% -32%	Extraordinary gains Extraordinary losses Income taxes, etc. Minority interests Net income	0.1 0.8 6.5 1.8 14.9	-100% -90% -72% -3%	< AprDec. Cumulative > ()=YoY change * Gain on transfer of benefit obligation relating to employees' pension fund ¥0.0 billion (¥27.8 billion decrease) * Gain on sales of shares in affiliated companies ¥2.3 billion (¥15.9 billion decrease) * Impairment losses
						¥0.2 billion (¥7.1 billion decrease)



### **AJINOMOTO** 2. Financial Position



# **AJINOMOTO**. 3. (1) Change by Business Segment





### **JINOMOTO**. 3. (2) Domestic Food Products

AprDec. 2013	Progress	AprDec. 2012	YoY Change		OctDec. 2013	OctDec. 2012	(¥ Billion) YoY Change
255.0	75%	314.1	-59.1	Net sales	93.8	92.9	0.9
164.2	-	167.7	-3.4	Seasonings & processed foods	63.0	62.8	0.1
90.8	-	87.0	3.7	Frozen foods	30.8	30.1	0.8
0.0	-	59.4	-59.4	Beverages ("Calpis")	0.0	0.0	0.0
22.8	83%	29.2	-6.4	Operating income	11.8	11.9	-0.1
24.0	-	24.7	-0.7	Seasonings & processed foods	12.1	11.2	0.9
4.2	-	6.8	-2.6	Frozen foods	1.5	2.4	-0.8
0.0	-	4.8	-4.8	Beverages ("Calpis")	0.0	-0.0	0.0
-5.5	73%	-7.2	1.7	Shared companywide expenses	-1.9	-1.7	-0.1

\*1 Q3 sales remained at level of previous Q3 as higher sales, mainly of *HON-DASHI*, offset effect of end of sales of beverage gifts resulting from disposal of Calpis shares.

\*2 Increase in Q3 sales because of contribution of sales overseas, mainly in North America, despite flat sales in Japan.

\*3 Q3 operating income was flat because lower income of frozen foods due to weaker yen and higher raw material prices, etc. offset higher income of seasonings & processed foods.



### **AJINOMOTO**. 3. (3) Overseas Food Products

(¥ Billion)

AprDec. 2013	Progress	AprDec. 2012	YoY Change		OctDec. 2013	OctDec. 2012	YoY Change	
219.4	<b>69%</b>	175.3	44.1	Net sales	74.9	60.5	14.4	
181.2	<b>68%</b>	142.2	39.0	Consumer foods	61.9	49.1	12.8	*1
38.2	73%	33.1	5.1	Umami seasonings for processed food mfrs.	13.0	11.4	1.6	*2
19.7	75%	15.4	4.3	Operating income	6.9	5.2	1.7	*3
-6.7	70%	-5.7	-1.0	Shared companywide expenses	-2.2	-1.7	-0.4	

[Effect of currency translation] Q3: Net sales +¥11.3 billion; operating income +¥1.3 billion Apr.-Dec.: Net sales +¥37.6 billion; operating income +¥4.7 billion

\*1 Increase in Q3 sales because of positive effect of currency translation and higher sales volume of umami seasoning *AJI-NO-MOTO*, flavor seasonings and processed foods, etc.

- \*2 Increase in Q3 sales because of positive effect of currency translation and higher sales volume of MSG, despite decrease in unit price.
- \*3 Increase in Q3 income due to higher income of consumer foods (\*1).

Reference (vs. previous Q3):

Consumer foods +¥2.4 billion; umami seasonings for processed food mfrs. -¥0.3 billion



### AJINOMOTO. 3. (4) Bioscience Products & Fine Chemicals (¥ Billion)

AprDec. 2013	Progress	AprDec. 2012	YoY Change		OctDec. 2013	OctDec. 2012	YoY Change
166.9	70%	146.4	20.5	Net sales	55.1	49.4	5.7
71.9	72%	68.9	3.0	Feed-use amino acids	24.4	23.7	0.8
58.0	-	45.2	12.9	Amino acids	18.6	15.0	3.6
33.0	-	28.6	4.3	Specialty chemicals	10.7	9.3	1.3
5.0	53%	11.3	-6.3	Operating income	1.1	4.1	-3.0
0.8	26%	10.5	-9.7	Feed-use amino acids	-0.1	4.2	-4.3
2.9	-	2.0	1.0	Amino acids	0.9	0.1	0.8
7.3	-	4.9	2.4	Specialty chemicals	2.2	1.4	0.8
-4.7	73%	-4.1	-0.6	Shared companywide expenses	-1.5	-1.2	-0.2

[Effect of currency translation] Q3: Net sales +¥7.8 billion; operating income +¥0.2 billion

Apr.-Dec.: Net sales +¥23.7 billion; operating income +¥0.7 billion

- \*1 Increase in Q3 sales because of positive effect of currency translation, despite substantial decrease in unit price.
- \*2 Q3 amino acids for pharmaceuticals and foods +¥1.2 billion; pharmaceutical custom manufacturing (formerly pharmaceutical fine chemicals) +¥2.1 billion; sweeteners +¥0.4 billion.
- \*3 Q3 sales of cosmetics and cosmetic ingredients remained at level of previous Q3. Q3 sales of specialty chemicals increased due to growth in sales of higher value-added electronics materials, etc.
- \*4 Decrease in Q3 income mainly due to lower income of feed-use amino acids.
  - Reference (vs. previous Q3):
  - Within amino acids, amino acids for pharmaceuticals and foods +¥0.3 billion; pharmaceutical custom manufacturing +¥0.3. billion; sweeteners +¥0.3 billion
- Note: Pharmaceutical custom manufacturing:
  - From Q1-FY2013, the results of Ajinomoto Althea, Inc. are included in this business.



(¥ Billion)

_	AprDec. 2013	Progress	AprDec. 2012	YoY Change		OctDec. 2013	OctDec. 2012	YoY Change
	38.8	75%	55.9	-17.1	Net sales	10.9	20.0	<b>-9.1</b> *1
	2.8	66%	4.6	-1.8	Operating income	1.3	2.8	<b>-1.5</b> *2
	-1.0	74%	-1.4	0.4	Shared companywide expenses	-0.3	-0.4	0.2

\*1 Decrease in Q3 sales of self-distributed products due to effect of spin-off of infusion and dialysis business units as AY PHARMACEUTICALS Co., Ltd. in July and change of segment for medical foods (Pharmaceuticals → Other Business), etc.

Q3 Sales of products sold through business tie-ups decreased because of lower royalty income.

Q3 sales based on AJINOMOTO PHARMACEUTICALS CO., LTD. estimated drug prices (% = change from previous Q3):

LIVACT	¥3.9 billion	(-2%)	ELENTAL	¥2.0 billion	(0%)
ATELEC	¥3.8 billion	(-9%)	ACTONEL	¥2.6 billion	(-14%)
FASTIC	¥0.5 billion	(-24%)			

\*2 Decrease in Q3 income due to lower royalty income, etc., despite improvement of operation efficiency.



(¥ Billion)

AprDec. 2013	Progress	AprDec. 2012	YoY Change		OctDec. 2013	OctDec. 2012	YoY Change
62.3	74%	55.2	7.0	Net sales	20.6	18.1	<mark>2.4</mark> *1
1.7	-	1.7	0.1	Edible oils & coffee products	0.6	0.6	0.0
0.4	109%	0.4	0.1	Operating income	0.2	0.1	<b>0.1</b> *2
1.7	-	1.6	0.1	Edible oils & coffee products	0.6	0.6	0.0
-2.1	<b>68%</b>	-2.0	-0.1	Shared companywide expenses	-0.7	-0.6	-0.1

\*1 Increase in Q3 sales due to impact of change of segment for medical foods (Pharmaceuticals → Other Business), etc.

\*2 Increase in Q3 income due to higher income in wellness business, etc.



# **JINOMOTO.** 3. (7) Net Sales by Business & Geographical Area

Upper row: Oct.-Dec. 2013; Iower row: Oct.-Dec. 2012 Figures in parentheses represent YoY change.

(¥ Billion)

	Japa	Japan		a	Americas		Europe		Total	
Domestic Food	88.9	(-0.4)	1.3	(0.0)	3.3	(1.2)	0.4	(0.1)	93.8	(0.9)
Products	89.2		1.2		2.1		0.3		92.9	
Overseas Food	2.6	(-0.1)	50.5	(9.7)	13.8	(3.3)	8.0	(1.5)	74.9	(14.4)
Products	2.7		40.8		10.5		6.5		60.5	
<b>Bioscience Products</b>	15.0	(0.7)	4.3	(0.7)	18.4	(2.3)	17.4	(1.9)	55.1	(5.7)
& Fine Chemicals	14.3		3.6		16.1		15.5		49.4	
Pharmaceuticals	10.9	(-9.1)							10.9	(-9.1)
	20.0								20.0	
Other Business	18.2	(2.1)	2.3	(0.3)	0.0	(0.0)			20.6	(2.4)
	16.1		2.0		0.0				18.1	
Total	135.6	(-6.8)	58.3	(10.7)	35.5	(6.8)	25.8	(3.6)	255.2	(14.3)
iotai	142.4		47.6		28.7		22.3		240.9	



# 

# 3. (8) Operating Income by Business & Geographical Area

Upper row: Oct.-Dec. 2013; lower row: Oct.-Dec. 2012 Figures in parentheses represent YoY change.

								(¥ Billion)				
	Japan		Asia		Americas		Europe		Other <sup>*</sup>		Total	
Domestic Food	12.8	(-0.4)	0.5	(0.3)	0.3	(0.1)	0.1	(0.0)	-1.9	(-0.2)	11.8	(-0.1)
Products	13.2		0.2		0.2		0.1		-1.8		11.9	
Overseas Food	-0.0	(0.2)	7.3	(1.5)	1.9	(0.7)	-0.2	(-0.4)	-2.1	(-0.4)	6.9	(1.7)
Products	-0.3		5.8		1.2		0.2		-1.7		5.2	
<b>Bioscience Products &amp; Fine</b>	2.3	(1.2)	-0.0	(-0.4)	0.1	(-2.3)	0.8	(-0.6)	-2.1	(-0.7)	1.1	(-3.0)
Chemicals	1.2		0.4		2.5		1.4		-1.4		4.1	
Pharmaceuticals	1.6	(-1.7)							-0.3	(0.2)	1.3	(-1.5)
	3.2								-0.4		2.8	
Other Business	0.8	(0.4)	0.2	(-0.0)	-0.0	(-0.0)	0.0	(-0.0)	-0.8	(-0.2)	0.2	(0.1)
	0.4		0.2		-0.0		0.1		-0.6		0.1	
Shared companywide	-3.3	(-0.2)	-2.1	(-0.6)	-1.1	(-0.3)	-0.8	(-0.2)	-7.2	(-1.3)		
expenses, etc.*	-3.1		-1.4		-0.7		-0.6		-5.9			
Total	14.2	(-0.4)	5.8	(0.7)	1.3	(-1.9)	-0.1	(-1.1)			21.3	(-2.8)
	14.7		5.2		3.2		1.1				24.0	

\* Shared companywide expenses and unrealized gains and losses not reflected in any geographical area, etc.



**A/B** 

# **AJINOMOTO.** 3. (9) Comments on Operating Income by Business & Geographical Area

Oct.-Dec. 2013 Change Compared with Same Period of Previous Year

#### **1. Overseas Food Products**

[YoY change]

(¥ Billion)

Japan +¥0.2; Asia +¥1.5; Americas +¥0.7; Europe -¥0.4; Other\* -¥0.4; Total +¥1.7

Asia: Increase due to positive effect of currency translation and higher sales of consumer foods products

#### 2. Bioscience Products & Fine Chemicals

[YoY change]

(¥ Billion)

Japan +¥1.2; Asia -¥0.4; Americas -¥2.3; Europe -¥0.6; Other\* -¥0.7; Total -¥3.0


America: Decrease mainly due to feed-use amino acids

\* Shared companywide expenses and unrealized gains and losses not reflected in any geographical area, etc.



#### (Reference)

### Feed-Use Lysine Market Price and CBOT Spread\* Trend





# Eat Well, Live Well.

- Forward-looking statements, such as business performance forecasts, made in these materials are based on management's estimates, assumptions and projections at the time of publication and do not represent a commitment from Ajinomoto Co., Inc. that they will be achieved. A number of factors could cause actual results to differ materially from expectations.
- > Unaudited figures are included in these materials for reference.
- > Amounts presented in these materials are rounded off.